75% reduction in incidence of meningitis B
(63 observed cases as compared with 253 expected cases; rate ratio: 0.25; 95% CI 0.19 to 0.36)
in a national immunisation programme in the United Kingdom1
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Significant impact in reducing the incidence of meningococcal B disease across countries, settings and target populations.1,2
No additional safety concerns in real world use beyond those identified in clinical trials in the UK and Canada.3,4
More than 50 million doses distributed worldwide.5